三角防務(300775.SZ)擬定增募資不超31.27億元 用於航天火箭箭體結構智能製造項目等等
格隆匯2月22日丨三角防務(300775.SZ)發佈向特定對象發行股票並在創業板上市預案,擬發行股票數量按照募集資金總額除以發行價格確定,同時此次發行股票數量不超過8000萬股(含),未超過此次發行前公司總股本的 30%。
募集資金總額不超過312724萬元,扣除發行費用後,29891.46萬元用於航空精密模鍛產業深化提升項目,48868.56萬元用於航空發動機葉片精鍛項目,65871.33萬元用於航空數字化集成中心項目,79128.09萬元用於航天火箭箭體結構智能製造項目,28964.56萬元用於先進航空零部件智能互聯製造基地項目,6億元用於補充流動資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.